Skill Checkup: A 62-Year-Old Man With Lumps on His Neck and Under His Arm

Ann S. LaCasce, MD, MMSc


May 25, 2023

If the patient achieves a partial response with aggressive induction chemotherapy, the most appropriate of the listed options for second-line therapy according to the NCCN guidelines would be a regimen containing a BTK inhibitor (ie, acalabrutinib, ibrutinib, and zanubrutinib). BTK is a pivotal protein for B-cell tumorigenesis. If a BTK inhibitor is contraindicated, combination therapy with an immunomodulator and an anti-CD20 antibody is recommended by the NCCN guidelines.

Although HDT/ASCR was the eventual plan intended for this patient following aggressive induction therapy, this option should be reserved for patients who were able to achieve complete response with front-line therapy. Second-line therapy should be considered in order to help the patient achieve complete response.

Chimeric antigen receptor T-cell therapy is recommended by the NCCN guidelines as a third-line option for relapsed/refractory MCL after chemoimmunotherapy and BTK inhibition.

Editor's Note: Skill Checkups are wholly fictional or fictionalized clinical scenarios intended to provide evidence-based educational takeaways.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.